Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712840 | 0.90 | ADORA1 (0.76) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL6993348 | 0.90 | ADORA1 (0.71) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7001243 | 0.89 | ADORA1 (0.70) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL6998249 | 0.89 | ADORA1 (0.70) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL6992778 | 0.87 | ADORA1 (0.67) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL12608918 | 0.85 | ADORA1 (0.82) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL5678867 | 0.85 | ADORA1 (0.71) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL1787090 | 0.85 | ADORA1 (1.00) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7001600 | 0.85 | ADORA1 (0.67) | ADORA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL5676492 | 0.84 | ADORA1 (0.72) | ADORA1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | ADORA1 847/4885MEN1 4548/4885KMT2A 2903/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | ADORA1 847/4885MEN1 4548/4885KMT2A 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.